|
[Related PubMed/MEDLINE]
Total Number of Papers: 3216
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. |
DMARDs, GVA |
| 2 |
2020 |
A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy. |
DMARDs, NHS |
| 3 |
2020 |
A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis. |
--- |
| 4 |
2020 |
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. |
ADA, csDMARDs, IXE |
| 5 |
2020 |
A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation. |
FP, HC, OSDI, PsO, SD-OCT |
| 6 |
2020 |
A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis. |
ECM, MMP |
| 7 |
2020 |
A novel treatment for psoriatic arthritis: Janus kinase inhibitors. |
JAK |
| 8 |
2020 |
A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile. |
CS, IL, IL-17A, qPCR, RORC |
| 9 |
2020 |
A proposal on how to assess the weight of the subjective components of the DAPSA in patients with psoriatic arthritis and comorbid fibromyalgia syndrome. |
DAPSA, DAPSA-P, FM, ROC |
| 10 |
2020 |
Accuracy of Physical Examination to Detect Synovial and Extra-Synovial Pathologies in Psoriatic Arthritis in Comparison to Ultrasonography. |
MCP, PABAK, PD, PE, PIP, US |
| 11 |
2020 |
Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis. |
IL, MDA, MTX |
| 12 |
2020 |
Adherence to Subcutaneous Anti-TNF Treatment in Chronic Inflammatory Rheumatism and Therapeutic Patient Education. |
anti-TNF, AS, RA, TPE |
| 13 |
2020 |
Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. |
AMP, IMI |
| 14 |
2020 |
Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. |
AA, HADS, IL |
| 15 |
2020 |
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. |
DMARD, HZ, IRs, MACE, NMSC |
| 16 |
2020 |
An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. |
CI, DAPSA, mMDA, OR |
| 17 |
2020 |
An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis. |
JAK, PsO |
| 18 |
2020 |
Analysis by Age Group of Disease Outcomes in Patients with Psoriatic Arthritis: A Cross-Sectional Multicentre Study. |
--- |
| 19 |
2020 |
Anti-cyclic citrullinated peptide antibody in psoriatic arthritis: ameta-analysis of its frequency and association with clinical features. |
anti-CCP, CI, OR |
| 20 |
2020 |
Antihistamines-refractory chronic pruritus in psoriatic patients undergoing biologics: aprepitant vs antihistamine double dosage, a real-world data. |
ESS, PRP |
| 21 |
2020 |
Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. |
HAQ, OMERACT, PROM, PROMIS |
| 22 |
2020 |
Apremilast and its role in psoriatic arthritis. |
DMARDs, TNF-alpha |
| 23 |
2020 |
Apremilast to treat oral ulcers in Behcet syndrome. |
Bsy, PDE4, Ps |
| 24 |
2020 |
Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. |
--- |
| 25 |
2020 |
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. |
BMI, FM, GUESS, LEI, MASES, PD, ROC |
| 26 |
2020 |
Assessment of serum levels of anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: A cross-sectional study in a Brazilian cohort. |
CCP |
| 27 |
2020 |
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. |
DAPSA, MDA, PASS, PsAID, VLDA |
| 28 |
2020 |
Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study. |
csDMARD |
| 29 |
2020 |
Association Between Comorbidities and Quality of Life in Psoriatic Arthritis: Results from a Multicentric Cross-sectional Study. |
CASPAR, MCS, mRDCI, PCS, QOL |
| 30 |
2020 |
Association between Leeds Dactylitis Index and ultrasonographic features: a multicentre study on psoriatic hand dactylitis. |
GS, LDI-b, PD, PIP |
| 31 |
2020 |
Association between uveitis and psoriatic disease: a systematic review and Meta-analysis based on the evidence from cohort studies. |
CIs, RRs |
| 32 |
2020 |
Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis. |
ADA, CASPAR, DMARDs, ETN, IFX, RF, TNF |
| 33 |
2020 |
Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. |
--- |
| 34 |
2020 |
Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. |
ADA, ADAb, HAQ, TNFi |
| 35 |
2020 |
Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. |
TNFi |
| 36 |
2020 |
Association Study between Psoriatic Arthritis and Killer Immunoglobulin-Like Receptor (KIR) Genes: A Meta-Analysis. |
KIR, OR |
| 37 |
2020 |
Associations between human leukocyte antigen C locus polymorphism and psoriatic arthritis in populations of European and Middle Eastern descent: a meta-analysis. |
HLA, OR |
| 38 |
2020 |
At the crossroads of gout and psoriatic arthritis: "psout". |
--- |
| 39 |
2020 |
Atlas of the OMERACT Heel Enthesitis MRI Scoring System (HEMRIS). |
HEMRIS, HEMRIS, OMERACT, SpA |
| 40 |
2020 |
Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab. |
Ab, ANA, DFS70, HCs, Ps |
| 41 |
2020 |
Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. |
CVD, IA, RA |
| 42 |
2020 |
Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement. |
ERA, JIA |
| 43 |
2020 |
Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes. |
RR |
| 44 |
2020 |
Birth Outcomes and Disease Activity During Pregnancy in a Prospective Cohort of Women With Psoriatic Arthritis and Ankylosing Spondylitis. |
aRRs, AS, HAQ, RAPID3 |
| 45 |
2020 |
Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. |
AS, IL-17, SLE, SS, SSc |
| 46 |
2020 |
Bristol rheumatoid arthritis fatigue scale is valid in patients with psoriatic arthritis and is associated with overall severe disease and higher comorbidities. |
CCI, FACIT-F |
| 47 |
2020 |
Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction. |
AoSI, AS, CV, LV, RA |
| 48 |
2020 |
Cardiovascular Disease in Spondyloarthritides. |
AS |
| 49 |
2020 |
Cardiovascular risk factors are highly overrepresented in Swedish patients with psoriatic arthritis compared with the general population. |
BMI |
| 50 |
2020 |
Cardiovascular risk in psoriatic arthritis, a narrative review. |
--- |
| 51 |
2020 |
Cartilage Degradation in Psoriatic Arthritis Is Associated With Increased Synovial Perfusion as Detected by Magnetic Resonance Imaging. |
DCE-MRI, dGEMRIC, DIP, JSW, MCP, PIP, PsAMRIS, RA, TCT |
| 52 |
2020 |
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. |
CZP |
| 53 |
2020 |
Challenges in the clinical diagnosis of psoriatic arthritis. |
--- |
| 54 |
2020 |
Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. |
cyno, IL, RA, TNF |
| 55 |
2020 |
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. |
DLQI, EQ VAS, WPAI |
| 56 |
2020 |
Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients. |
AS, IGRA, LTBI, NNH, RA |
| 57 |
2020 |
Circulating microRNAs in extracellular vesicles as potential biomarkers for psoriatic arthritis in patients with psoriasis. |
EVs, PsC |
| 58 |
2020 |
Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life. |
BL, CZP, PASI, PsO |
| 59 |
2020 |
Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome. |
AS, LVM, MetS, RA |
| 60 |
2020 |
Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. |
DI, DMARDs, ES, PF, PROMs, RCTs, SF-36 PCS |
| 61 |
2020 |
Clinical, Serological and Immunological Characteristics in Greek Patients with Psoriatic Arthritis: The Role of IL-17, IL-23, and Sclerostin. |
AS, NW, SpA, TNF, TNFi |
| 62 |
2020 |
Combined manual and automated immunophenotypisation identified disease-specific peripheral blood immune subpopulations in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. |
AS, RA |
| 63 |
2020 |
Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. |
aHR, AS, csDMARD, MTX, RA, SpA, TNFi |
| 64 |
2020 |
Comparative results of the implementation in daily practice of an evaluation checklist for patients with axial spondyloarthritis and psoriatic arthritis. |
axSpA |
| 65 |
2020 |
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. |
CIs, HRs, IL, IRs, PsO, TNF |
| 66 |
2020 |
Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. |
DMARDs, PsO, RA, TNFi |
| 67 |
2020 |
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). |
ACR, DAPSA, DMARD, HAQ, LEF, MDA, MTX, PASDAS, PSAID, SF-12 |
| 68 |
2020 |
Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. |
MCP, MRI, OMERACT, PIP, PsAMRIS, SRM, StdC, TC, TICOPA, US |
| 69 |
2020 |
Comparing the patient reported physical function outcome measures in a real-life international cohort of patients with psoriatic arthritis. |
HAQ-DI, PCS12, PROMs, PsAID-FC |
| 70 |
2020 |
Comparison of bone structure and microstructure in the metacarpal heads between patients with psoriatic arthritis and healthy controls: an HR-pQCT study. |
HR-pQCT, MCH, vBMD |
| 71 |
2020 |
Comparison of carotid artery ultrasound and Framingham risk score for discriminating coronary artery disease in patients with psoriatic arthritis. |
CAD, CCTA, CIMT, CV, FRS, O-CAD, TPA, US |
| 72 |
2020 |
Comparison of Hospital Anxiety and Depression Scale (HADS) and Zung Self-Rating Anxiety/Depression Scale (SAS/SDS) in Evaluating Anxiety and Depression in Patients with Psoriatic Arthritis. |
HADS, PGA, SAS/SDS |
| 73 |
2020 |
Complementary and Alternative Medicine Use in Psoriatic Arthritis Patients: a Review. |
CAM |
| 74 |
2020 |
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. |
DAPSA, mCPDAI, PASDAS |
| 75 |
2020 |
Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis. |
CASPAR, CI, LV, LVSD, OR |
| 76 |
2020 |
Conducting research in psoriatic arthritis: the emerging role of patient research partners. |
PRP |
| 77 |
2020 |
Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. |
ASAS-HI, AUC, DAPSA, PsAID |
| 78 |
2020 |
Content validity of psoriatic arthritis screening questionnaires: systematic review. |
PROMs, PsO |
| 79 |
2020 |
Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis. |
MS |
| 80 |
2020 |
Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. |
CASPAR, MBDA, RA, UCSD |
| 81 |
2020 |
Correlations of fatigue in Danish patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis. |
axSpA, HAQ, MDI, MOS, PROs, RA, WPAI |
| 82 |
2020 |
Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany. |
DMARDs, HAQ, ICERs |
| 83 |
2020 |
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK. |
bDMARD, BSC, CEAs, IL-17A, PsARC, QALYs |
| 84 |
2020 |
Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States. |
ACR, ADRs, csDMARD, IR, NICE, TNFi |
| 85 |
2020 |
Cross-cultural validation and psychometric properties of the Brazilian Portuguese version of the Psoriasis Epidemiology Screening Tool (PEST-bp). |
DLQI, PEST |
| 86 |
2020 |
Curcumin mediates attenuation of pro-inflammatory interferon gamma and interleukin 17 cytokine responses in psoriatic disease, strengthening its role as a dietary immunosuppressant. |
CD, IFN, IL, NK, STAT |
| 87 |
2020 |
Current knowledge on autoantigens and autoantibodies in psoriasis. |
--- |
| 88 |
2020 |
Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project. |
--- |
| 89 |
2020 |
Current understanding and future perspectives of brain-heart-kidney axis in psoriatic arthritis. |
CVD, MRI |
| 90 |
2020 |
DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. |
CIMT, CP, CV, CVD, DAPSA |
| 91 |
2020 |
Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker? |
--- |
| 92 |
2020 |
Defining Pre-Clinical Psoriatic Arthritis in an Integrated Dermato-Rheumatology Environment. |
ACPA, PsO |
| 93 |
2020 |
Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis. |
CV, MS-PSO |
| 94 |
2020 |
Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. |
bDMARDs |
| 95 |
2020 |
Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. |
DAPSA, PR |
| 96 |
2020 |
Development and initial validation of a questionnaire to assess facilitators and barriers to physical activity for patients with rheumatoid arthritis, axial spondyloarthritis and/or psoriatic arthritis. |
axSpA, IA, mHAQ, PA, RA |
| 97 |
2020 |
Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. |
PASQAL |
| 98 |
2020 |
Development of a Modified Psoriatic Arthritis Disease Activity Score Using the Medical Outcomes Study Short Form 12 as a Measure of Quality of Life. |
mPASDAS, PASDAS, SF-36 |
| 99 |
2020 |
Development or worsening of sarcoidosis associated with IL-17 blockade for psoriasis. |
IL |
| 100 |
2020 |
Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. |
AUC |
|
A Search Service for Abbreviation / Long Form
